ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States

Post author:admERY
Post published:July 22, 2014
Post category:Newsroom

ERYTECH announces the enrollment of the first patient in its Phase I/II study with eryaspase in Acute Lymphoblastic Leukemia in the United States of America.

You Might Also Like

ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

ERYTECH announces positive DSMB annual review of its Expanded Access Program in ALL